Literature DB >> 24522845

Pons herniation into skull base after cabergoline therapy of giant prolactinoma.

Jesús Moles Herbera1, David Rivero Celada, Inmaculada Montejo Gañan, David Fustero de Miguel, Carlos Fuentes Uliaque, Ana Carmen Vela Marín.   

Abstract

INTRODUCTION: Pons herniation after cabergoline therapy for giant prolactinoma is a complication not documented in literature. CASE REPORT: We report a medium aged patient who developed secondary hemiparesis after 18 months of medical treatment. MRI revealed pons herniation into the clivus. There was improvement with conservative treatment. Secuencial MRIs are presented showing the tumor at the moment of the diagnosis, tumor shrinkage and pons herniation. DISCUSSION: Some studies have shown that a significant and rapid tumor shrinkage resulting from treatment with cabergoline can occur and it is thought that some complications are related with this tumor regression, as in the presented case.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24522845     DOI: 10.1007/s11102-014-0558-9

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  13 in total

Review 1.  CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas.

Authors:  K S Leong; P M Foy; A C Swift; S L Atkin; D R Hadden; I A MacFarlane
Journal:  Clin Endocrinol (Oxf)       Date:  2000-01       Impact factor: 3.478

2.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.

Authors:  E Delgrange; J Trouillas; D Maiter; J Donckier; J Tourniaire
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

Review 3.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.

Authors:  Shlomo Melmed; Felipe F Casanueva; Andrew R Hoffman; David L Kleinberg; Victor M Montori; Janet A Schlechte; John A H Wass
Journal:  J Clin Endocrinol Metab       Date:  2011-02       Impact factor: 5.958

Review 4.  Treatment of pituitary tumors: dopamine agonists.

Authors:  Gabriella Iván; Nikoletta Szigeti-Csúcs; Márk Oláh; György M Nagy; Miklós I Góth
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

5.  Optic chiasmal herniation--an under recognized complication of dopamine agonist therapy for macroprolactinoma.

Authors:  S E Jones; R A James; K Hall; P Kendall-Taylor
Journal:  Clin Endocrinol (Oxf)       Date:  2000-10       Impact factor: 3.478

6.  Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.

Authors:  Gérald Raverot; Maud Jacob; Emmanuel Jouanneau; Brigitte Delemer; Alain Vighetto; Michel Pugeat; Françoise Borson-Chazot
Journal:  Clin Endocrinol (Oxf)       Date:  2008-07-31       Impact factor: 3.478

7.  Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma.

Authors:  Dinesh Kumar Dhanwal; Ashok Kumar Sharma
Journal:  Pituitary       Date:  2009-04-19       Impact factor: 4.107

8.  Giant prolactinomas in men: efficacy of cabergoline treatment.

Authors:  S M Corsello; G Ubertini; M Altomare; R M Lovicu; M G Migneco; C A Rota; C Colosimo
Journal:  Clin Endocrinol (Oxf)       Date:  2003-05       Impact factor: 3.478

Review 9.  Giant prolactinomas: the therapeutic approach.

Authors:  Aline B Moraes; Cintia Marques dos Santos Silva; Leonardo Vieira Neto; Mônica R Gadelha
Journal:  Clin Endocrinol (Oxf)       Date:  2013-06-11       Impact factor: 3.478

10.  Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.

Authors:  Eun-Hee Cho; Sang Ah Lee; Ji Youn Chung; Eun Hee Koh; Young Hyun Cho; Jeong Hoon Kim; Chang Jin Kim; Min-Seon Kim
Journal:  J Korean Med Sci       Date:  2009-09-24       Impact factor: 2.153

View more
  1 in total

1.  Brain and Optic Chiasm Herniation into Sella after Pituitary Tumor Apoplexy.

Authors:  Maria M Pineyro; Patricia Furtenbach; Ramiro Lima; Saul Wajskopf; Nicolas Sgarbi; Raul Pisabarro
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-07       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.